Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
Blood Advances
|
July 14, 2023
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Federico Stella, Vincenzo Marasco, Giorgia Virginia Levati, et al.
Blood Advances
|
February 15, 2024
Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma
Cristiana Carniti, Nicole M Caldarelli, Luca Agnelli, et al.
Blood Cancer Journal
|
November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myeloma
Kyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study
Nicole Fabbri, Beatrice Casadei, Annalisa Chiappella, et al.
British Journal of Haematology
|
December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
Federico Stella, Annalisa Chiappella, Martina Magni, et al.
Blood Advances
|
August 5, 2025
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis
Anna Dodero, Giusy Ceparano, Beatrice Casadei, et al.
The New England Journal of Medicine
|
June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Marco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Haematologica
|
May 29, 2025
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
Martina Magni, Sadhana Jonnalagadda, Francesca Bonifazi, et al.
Blood Advances
|
May 5, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study
Giulia Gabrielli, Beatrice Casadei, Annalisa Chiappella, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
Blood Advances
|
July 14, 2023
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial
Federico Stella, Vincenzo Marasco, Giorgia Virginia Levati, et al.
Blood Advances
|
February 15, 2024
Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma
Cristiana Carniti, Nicole M Caldarelli, Luca Agnelli, et al.
Blood Cancer Journal
|
November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myeloma
Kyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Bone Marrow Transplantation
|
June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)
Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 16, 2026
Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study
Nicole Fabbri, Beatrice Casadei, Annalisa Chiappella, et al.
British Journal of Haematology
|
December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
Federico Stella, Annalisa Chiappella, Martina Magni, et al.
Blood Advances
|
August 5, 2025
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis
Anna Dodero, Giusy Ceparano, Beatrice Casadei, et al.
The New England Journal of Medicine
|
June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Marco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Haematologica
|
May 29, 2025
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
Martina Magni, Sadhana Jonnalagadda, Francesca Bonifazi, et al.
Blood Advances
|
May 5, 2026
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study
Giulia Gabrielli, Beatrice Casadei, Annalisa Chiappella, et al.
Page
of 7